The leading provider of digital signature solutions (standard electronic signatures) to the life sciences and healthcare industries, ARX (Algorithmic Research), announced today that it has become a vendor partner of the non-profit that manages the SAFE-BioPharma™ digital identity and signature standard for the pharmaceutical and healthcare industries, SAFE-BioPharma Association.Recent changes in the criteria maintained by SAFE-BioPharma now permit SAFE-BioPharma member companies to deploy centralized server-based PKI digital signature solutions, such as ARX's CoSign digital signature solution. The most widely used digital signature technology in the industry is ARX's CoSign. SAFE-BioPharma user credentials, with CoSign, can be accessed centrally from a network, or web portal, and utilized for signing from any location at any time.
Life Sciences and Healthcare Manager, ARX, Rodd Schlerf, explained:
"This advancement will enable companies to implement the strong user identity in the credentialing model put forth by SAFE-BioPharma, with the affordable, secure, and easy-to-use CoSign solution that eliminates client side tokens, smartcards, and software". CEO, SAFE-BioPharma Association, Mollie Shields-Uehling, said: "We are pleased to welcome ARX to the SAFE-BioPharma Vendor Partner Program".
SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharma™ digital identity and signature standard for the pharmaceutical and healthcare industries. The SAFE-BioPharma industry standard is used to mitigate legal, regulatory and other business risk associated with business-to-business and business-to-regulator electronic transactions. By providing a secure, enforceable, and regulatory-compliant way to verify identities of parties involved in electronic transactions, it facilitates interoperability. To be a catalyst in transforming the biopharmaceutical and healthcare communities to a fully electronic business environment by 2012 is SAFE-BioPharma's vision. The Association's members include AstraZeneca, Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Genzyme, Johnson & Johnson, Merck, Procter & Gamble, Pfizer, Roche and Sanofi-Aventis.
Software Security Solutions, Inc., a technology firm specializing in security solutions for small and medium-sized businesses, published a guide to aid firms in the task of building layered security protection for vulnerable networked environments. The guide helps clarify how SMBs should evaluate anti-virus software and includes links to independent testing laboratories that provide unbiased reports on all major players as well as the increasingly important "second-tier" companies in the anti-virus field.
